laquinimod: Clinical Trials

6 trials of laquinimod, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 2 terminated, 1 withdrawn. 6 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 36Completed 3, Terminated 2, Withdrawn 1

Follow laquinimod: new trials by email Literature Review of laquinimod trials Research Report on laquinimod

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
Laquinimod, Avonex® - Relapsing Remitting Multiple Sclerosis
Phase 3WithdrawnTeva Branded Pharmaceutical Products R&D, Inc.2014-01-012021-11-09
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
Laquinimod, Placebo - Multiple Sclerosis
Phase 3CompletedTeva Branded Pharmaceutical Products R&D, Inc.21992013-02-202021-11-09
A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis
Laquinimod - Relapsing Multiple Sclerosis
Phase 3TerminatedTeva Branded Pharmaceutical Products R&D, Inc.10472010-05-272021-12-09
A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course
Laquinimod - Relapsing Multiple Sclerosis
Phase 3TerminatedTeva Branded Pharmaceutical Products R&D, Inc.8392009-11-102021-12-09
BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)
Laquinimod, Placebo, Avonex® - Multiple Sclerosis
Phase 3CompletedTeva Branded Pharmaceutical Products R&D, Inc.13312008-04-242022-04-21
Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)
Laquinimod, Placebo - Multiple Sclerosis
Phase 3CompletedTeva Branded Pharmaceutical Products R&D, Inc.11062007-11-132021-11-02

Conditions studied

Multiple Sclerosis (3)  ·  Multiple Sclerosis, Relapsing-Remitting (1)  ·  Recurrence (1)

Sponsors

Teva Branded Pharmaceutical Products R&D, Inc. (6)

Countries

Bulgaria (5)  ·  Czechia (5)  ·  Estonia (5)  ·  Georgia (5)  ·  Germany (5)  ·  Israel (5)  ·  Italy (5)  ·  Poland (5)  ·  Romania (5)  ·  Russia (5)  ·  Spain (5)  ·  Ukraine (5)  ·  United States (5)  ·  Lithuania (4)  ·  Austria (3)

Top investigators

Giancarlo Comi (1)  ·  Giancarlo Comi, Prof., MD (1)  ·  Prof. Timothy Vollmer, MD (1)

Results publications

PMID 26000222, PMID 22417253, PMID 24029546, PMID 34378456, PMID 36163349

NIH funding

2009 (2)